News

July 12, 2019July 12, 2019

Libtayo Approved in Europe to Treat Metastatic or Advanced Cutaneous Squamous Cell Carcinoma

News

Libtayo (cemiplimab) has been conditionally approved to be sold in the European Union for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), one of ... Read more

July 10, 2019

Trial Will Test Thermal Ablation, Followed By IP-001 Immunotherapy, Against Solid Tumors

News

Immunophotonics and Clinical Laserthermia Systems (CLS) are teaming up in a Phase 1/2 trial to explore the safety and effectiveness of a thermal ablation approach — destruction of tissue by ... Read more

July 9, 2019July 9, 2019

Cancer Vaccine VBI-1901 Well-Tolerated in Recurrent Glioblastoma Patients, Early Phase 1/2a Data Show

News

Treatment of recurrent glioblastoma with the investigational cancer vaccine VBI-1901 was well-tolerated and associated with stable disease in a subset of patients, according to findings of a Phase 1/2a trial. ... Read more

July 3, 2019

Imfinzi Combo Therapy Extends Survival of Advanced SCLC Patients, Phase 3 Trial Shows

News

Adding Imfinzi (durvalumab) to standard first-line chemotherapy led to a clinically meaningful extension in the overall survival of patients with advanced small cell lung cancer (SCLC), according to results of ... Read more

July 2, 2019

DPX-Survivac-Keytruda Trio Shows Promise in DLBCL Patients

News

IMV‘s lead candidate, DPX-Survivac, in combination with Keytruda (pembrolizumab) and low-dose intermittent cyclophosphamide, eliminated radiologic traces of cancer cells in one-third of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients ... Read more

June 28, 2019June 28, 2019

Complete Remission Induced in B-cell ALL Patients After Single Dose of FasT CAR-19 Therapy, Preliminary Data Show

News

A single infusion of an experimental cell therapy called FasT CAR-19 was well-tolerated and induced a complete remission in all B-cell acute lymphoblastic leukemia (B-ALL) patients included in a Phase ... Read more

June 26, 2019

Tislelizumab Produces Promising Anti-Cancer Activity in Advanced Nasopharyngeal Cancer Patients, Preliminary Data Show

News

BeiGene’s investigational anti-PD-1 inhibitor tislelizumab is well-tolerated and showed early signs of efficacy in patients with advanced nasopharyngeal cancer, with more than 40% of patients achieving a response to treatment, ... Read more

June 25, 2019June 25, 2019

Keytruda Found to be Safe as Cancer Treatment for HIV Patients, Phase 1 Trial Shows

News

The immune checkpoint inhibitor Keytruda (pembrolizumab) was found to be a safe treatment for different cancer types among people living with HIV, data from a Phase 1 trial show. The results are ... Read more

June 21, 2019

Bemcentinib-Keytruda Combo Provides Durable Response in Advanced NSCLC, Phase 2 Trial Shows

News

Combining bemcentinib with Keytruda (pembrolizumab) has shown efficacy and led to longer survival than previous second-line treatments in patients with advanced non-small cell lung cancer (NSCLC), according to updated results ... Read more

June 19, 2019

FDA Grants Fast Track Status to Immunotherapy Candidate TRQ-1501 for Some Solid Tumors, Lymphomas

News

TRQ-1501, an experimental immune cell cancer therapy developed by Torque, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of certain hard-to-treat solid ... Read more